Citius Pharmaceuticals Reports FY GAAP EPS of -$3.38, Misses Estimate by $0.25

Citius Pharmaceuticals reported a FY GAAP EPS of -$3.38, missing expectations by $0.25. The company had cash and cash equivalents of $4.3 million as of September 30, 2025, and R&D expenses were $9.2 million for the full year, compared to $11.9 million in the previous year.